ஏ ராய் டோர்ஸி News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Digital technology driving tangible advancements in Parkinson s disease research and clinical care
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
Digital technology driving tangible advancements in Parkinson s disease research and clinical care
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Haze May Be Clearing in Parkinson s Disease
medpagetoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medpagetoday.com Daily Mail and Mail on Sunday newspapers.
Editor of the Reformer:
Dear Legislative Leaders,
In May of 2016 I was diagnosed with Parkinsonâs disease. Since them I have witnessed a degradation in mobility and cognitive functioning. I am fortunate to be living in a time where drugs and exercise have a combined effect at slowing the diseaseâs progression; however, no cure exists.
With the above in mind I would like the state of Vermont to begin the collection of data as it relates to the tracing of Parkinsonâs. As outlined in âThe Rise of Parkinsonâs Diseaseâ (E. Ray Dorsey, Todd Sherer, Michael S. Okun, Bastiaan R. Bloem for American Scientist) research reveals the rise of Parkinsonâs in rural areas likely elevated by the presence of the following: paraquat, rotenone and trichlorethylene. The first two are used in agricultural applications while the latter is used in âwashing away grease, cleaning silicon wafers, removing spots in dry cleaning.â Current evidence exists linking the
Eisai to Launch Parkinson s Disease Treatment Equfina in South Korea
TOKYO, Feb 1, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that Eisai Korea Inc., Eisai s subsidiary in South Korea, has launched the Parkinson s disease treatment Equfina (safinamide mesilate, safinamide ). This is the first launch of Equfina in the Asian region excluding Japan.
The estimated number of patients with Parkinson s disease is approximately 150,000 in South Korea. Parkinson s disease has high unmet medical needs because of inadequate symptom control using current medications, necessitating new treatment options. This disease is designated as a rare intractable disease in South Korea.
The marketing approval of this drug in South Korea is primarily based on a double-blind, placebo-controlled, Phase III Study (SETTLE study) conducted overseas (including South Korea) to evaluate the efficacy and safety of 24-week oral administration of the once-daily safinamide as an add-on to levodopa in pat